Macrogenics (MGNX) Receivables - Other (2014 - 2026)
Macrogenics (MGNX) posted quarterly Receivables - Other of $900000.0 for Q3 2015, up 118.18% year-over-year from $412500.0 in Q3 2014, and up 12.5% quarter-over-quarter from $800000.0 in Q2 2015.
Powered by 
Analysis
Macrogenics (MGNX) Receivables - Other (2014 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported Receivables - Other for 2 consecutive years, with $900000.0 the latest figure, recorded in Q3 2015.
- In Q3 2015, Receivables - Other rose 118.18% year-over-year to $900000.0; the TTM figure through Sep 2015 stood at $900000.0 (up 118.18% YoY), while the FY2014 annual figure was $500000.0, changed N/A from the prior year.
- Receivables - Other climbed to $900000.0 in Q3 2015 per MGNX's latest filing, from $800000.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $900000.0 in Q3 2015 and bottomed at $0.6 in Q1 2015.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Macrogenics | 284.90 Mn | 171.00 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 119.58 Mn |
| Sep 30, 2015 | 900,000.00 |
| Jun 30, 2015 | 800,000.00 |
| Mar 31, 2015 | 0.60 |
| Dec 31, 2014 | 500,000.00 |
| Sep 30, 2014 | 412,500.00 |